-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CFlWWmKYC1jo0yMmOf1u8ueBFOCxCg91+AdNr26z109yAp6zj0+nYyOff8oHpg7O 9ZA02nFB4dNN50i8ZrUH2Q== 0001144204-03-003404.txt : 20030630 0001144204-03-003404.hdr.sgml : 20030630 20030627181023 ACCESSION NUMBER: 0001144204-03-003404 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030626 ITEM INFORMATION: Other events FILED AS OF DATE: 20030630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CALYPTE BIOMEDICAL CORP CENTRAL INDEX KEY: 0000899426 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 061226727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-20985 FILM NUMBER: 03762367 BUSINESS ADDRESS: STREET 1: 1265 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502- BUSINESS PHONE: 5107495100 MAIL ADDRESS: STREET 1: 1265 HARBOR BAY PKWY CITY: ALAMEDA STATE: CA ZIP: 94502 8-K 1 doc1.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2003 ------------------ CALYPTE BIOMEDICAL CORPORATION. -------------------------------- Exact name of Registrant as specified in its Charter) DELAWARE -------- (State or other jurisdiction of incorporation) 000-20985 06-1226727 - --------- ---------- Commission File No. I.R.S. Employer Identification 1265 Harbor Bay Parkway, Alameda, CA 94502 - ----------- ----- Address of principal executive offices Zip Code (510) 749-5100 - -------------- Registrant's telephone number, including area code ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE On June 27, 2003 the Registrant (the "Company") entered into a Separation Agreement, mutual release and waiver of claims with Nancy E. Katz, the Company`s former Chief Executive Officer effective June 2, 2003. Ms. Katz also currently resigned as a director of the Company, and did not have any disagreement with the Company`s operations, policies or practices. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS 99.1 Calypte Biomedical Press Release dated June 27, 2003. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: Alameda, California June 27, 2003 CALYPTE BIOMEDICAL CORPORATION (Registrant) /s/ Richard D. Brounstein ---------------------------------- Richard D. Brounstein Executive Vice President and Chief Financial Officer EX-99.1 3 doc2.txt Exhibit 99.1 [CALYPTE BIOMEDICAL CORPORATION LOGO] NEWS RELEASE - ------------------------------------------------------------------------------- 1265 Harbor Bay Parkway o Alameda, CA 94502 www.calypte.com Investor Relations Contact: Joe Bunning, Sitrick & Company (310) 788-2850 email: joe_bunning@Sitrick.com CALYPTE ANNOUNCES SENIOR MANAGEMENT CHANGE NANCY KATZ TO DEPART THE COMPANY ALAMEDA, CALIF. - JUNE 27, 2003 -Calypte Biomedical Corporation (OTCBB: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, today announced that effective immediately Nancy Katz will leave the company. "We appreciate Nancy's contributions and dedication during her tenure as Calypte's President and CEO for the past three years," said Anthony Cataldo, Executive Chairman of Calypte Biomedical. "Nancy is leaving to pursue other interests." Ms. Katz has elected to give up her seat on the company's Board. About Calypte Biomedical: - ------------------------ Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com. # # # Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC. -----END PRIVACY-ENHANCED MESSAGE-----